CytoMed Therapeutics GDTC
NASDAQ GDTC
$0.91 +0.04 (+4.42%)
As of: Oct 21, 2026 · 3:59 PM EDT

CytoMed Therapeutics (GDTC) Retained Earnings (2021 - 2026)

Updated

CytoMed Therapeutics (GDTC) reported Retained Earnings of -$20.6 million for Q2 2026, compared with -$17.09 million a year earlier.

Analysis

CytoMed Therapeutics (GDTC) Retained Earnings (2021 - 2026) Analysis & Trends

At the end of FY2025, CytoMed Therapeutics posted Retained Earnings of -$14.41 million.

  • By year, Retained Earnings came in at -$11.12 million in FY2024, -$9.18 million in FY2023, -$5.95 million in FY2022 and -$3.77 million in FY2021.
  • The Q2 2026 figure ranks as the lowest quarterly Retained Earnings in data going back to Q4 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Retained Earnings (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 31.89 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 171.67 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -17.33 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 63.27 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 12.59 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -22.28 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 2.20 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 112.09 Bn
10 CytoMed Therapeutics 9.44 Mn -158,924.18 - -20.60 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -20.60 Mn
Dec 31, 2025 -14.67 Mn
Jun 30, 2025 -17.09 Mn
Dec 31, 2024 -10.92 Mn
Jun 30, 2024 -13.42 Mn
Dec 31, 2023 -9.34 Mn
Jun 30, 2023 -10.36 Mn
Dec 31, 2022 -6.10 Mn
Dec 31, 2021 -3.75 Mn
API Access

CytoMed Therapeutics Retained Earnings API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=retained-earnings&ticker=GDTC&period=max&api_key=YOUR_API_KEY